» Articles » PMID: 22231296

Quality of Life Issues in Men Undergoing Androgen Deprivation Therapy: a Review

Overview
Journal Asian J Androl
Specialty Urology
Date 2012 Jan 11
PMID 22231296
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Androgen deprivation therapy (ADT) has been an essential treatment option for treating prostate cancer (PCa). The role for hormonal treatment initially was restricted to men with metastatic and inoperable, locally advanced disease. Now it has been extended to neoadjuvant or adjuvant therapy for surgery and radiotherapy, for biochemical relapse after surgery or radiation, and even as primary therapy for non-metastatic disease. Fifty percent of PCa patients treated will receive ADT at some point. There is growing concern about the adverse effects and costs associated with more widespread ADT use. The adverse effects on quality of life (QoL), including physical, social and psychological well-being when men are androgen-deprived, may be considerable. This review examines the QoL issues in the following areas: body feminisation, sexual changes, relationship changes, cognitive and affective symptoms, fatigue, sleep disturbance, depression and physical effects. Further suggestions for therapeutic approaches to reduce these alterations are suggested.

Citing Articles

Prostate Cancer Survivorship Essentials for men with prostate cancer on androgen deprivation therapy: protocol for a randomised controlled trial of a tele-based nurse-led survivorship care intervention (PCEssentials Hormone Therapy Study).

Green A, Newton R, Smith D, Tuffaha H, Galvao D, Heathcote P BMJ Open. 2024; 14(3):e084412.

PMID: 38521521 PMC: 10961537. DOI: 10.1136/bmjopen-2024-084412.


Factors predicting gains in moderate-to-vigorous physical activity in prostate cancer survivors on androgen deprivation therapy.

Papadopoulos E, Leach H, Tomlinson G, Durbano S, Danyluk J, Sabiston C Support Care Cancer. 2022; 30(11):9011-9018.

PMID: 35948848 DOI: 10.1007/s00520-022-07300-2.


The impact of hegemonic masculine ideals on self-esteem in prostate cancer patients undergoing androgen deprivation therapy (ADT) compared to ADT-naïve patients.

Gentili C, McClean S, McGeagh L, Bahl A, Persad R, Harcourt D Psychooncology. 2022; 31(11):1958-1971.

PMID: 35833603 DOI: 10.1002/pon.6001.


Impacts of Neoadjuvant Hormonal Therapy Prior to Robot-Assisted Radical Prostatectomy on Postoperative Hormonal- and Sexual-Related Quality of Life - Assessment by Patient-Reported Questionnaire.

Ogawa S, Hasegawa A, Makabe S, Onagi A, Matsuoka K, Kayama E Res Rep Urol. 2022; 14:39-48.

PMID: 35223660 PMC: 8865904. DOI: 10.2147/RRU.S342063.


Feasibility, Acceptability, and Clinical Significance of a Dyadic, Web-Based, Psychosocial and Physical Activity Self-Management Program () Tailored to the Needs of Men with Prostate Cancer and Their Caregivers: A Multi-Center Randomized Pilot Trial.

Lambert S, Duncan L, Culos-Reed S, Hallward L, Higano C, Loban E Curr Oncol. 2022; 29(2):785-804.

PMID: 35200566 PMC: 8871005. DOI: 10.3390/curroncol29020067.


References
1.
Shahinian V, Kuo Y, Freeman J, Goodwin J . Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med. 2006; 166(4):465-71. PMC: 2222554. DOI: 10.1001/archinte.166.4.465. View

2.
Maki P, Sundermann E . Hormone therapy and cognitive function. Hum Reprod Update. 2009; 15(6):667-81. PMC: 2759330. DOI: 10.1093/humupd/dmp022. View

3.
Dacal K, Sereika S, Greenspan S . Quality of life in prostate cancer patients taking androgen deprivation therapy. J Am Geriatr Soc. 2006; 54(1):85-90. DOI: 10.1111/j.1532-5415.2005.00567.x. View

4.
Dorff T, Vogelzang N . Use of testosterone replacement therapy in patients with prostate cancer. Curr Urol Rep. 2011; 12(3):223-8. DOI: 10.1007/s11934-011-0176-2. View

5.
Harrington J, Badger T . Body image and quality of life in men with prostate cancer. Cancer Nurs. 2009; 32(2):E1-7. DOI: 10.1097/NCC.0b013e3181982d18. View